These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 30587450)

  • 61. Beyond the Rule of 5: Impact of PEGylation with Various Polymer Sizes on Pharmacokinetic Properties, Structure-Properties Relationships of mPEGylated Small Agonists of TGR5 Receptor.
    Hoguet V; Lasalle M; Maingot M; Dequirez G; Boulahjar R; Leroux F; Piveteau C; Herledan A; Biela A; Dumont J; Chávez-Talavera O; Belloy L; Duplan I; Hennuyer N; Butruille L; Lestavel S; Sevin E; Culot M; Gosselet F; Staels B; Deprez B; Tailleux A; Charton J
    J Med Chem; 2021 Feb; 64(3):1593-1610. PubMed ID: 33470812
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
    Li Z; Qiu Q; Xu X; Wang X; Jiao L; Su X; Pan M; Huang W; Qian H
    Eur J Med Chem; 2016 May; 113():246-57. PubMed ID: 26945112
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Discovery of DS-3801b, a non-macrolide GPR38 agonist with N-methylanilide structure.
    Toda N; Shida T; Takano R; Katagiri T; Hirouchi M; Abe M; Soma K; Nakagami Y; Yamazaki M
    Bioorg Med Chem Lett; 2022 Mar; 59():128554. PubMed ID: 35051575
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition.
    Goyard D; Kónya B; Chajistamatiou AS; Chrysina ED; Leroy J; Balzarin S; Tournier M; Tousch D; Petit P; Duret C; Maurel P; Somsák L; Docsa T; Gergely P; Praly JP; Azay-Milhau J; Vidal S
    Eur J Med Chem; 2016 Jan; 108():444-454. PubMed ID: 26708111
    [TBL] [Abstract][Full Text] [Related]  

  • 65. 3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists.
    Walsh SP; Severino A; Zhou C; He J; Liang GB; Tan CP; Cao J; Eiermann GJ; Xu L; Salituro G; Howard AD; Mills SG; Yang L
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3390-4. PubMed ID: 21514824
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles.
    Guo B; Guo S; Huang J; Li J; Li J; Chen Q; Zhou X; Xie X; Yang Y
    Bioorg Med Chem; 2018 Dec; 26(22):5780-5791. PubMed ID: 30392954
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Discovery and optimization of cyclohexane-1,4-diamines as allosteric MALT1 inhibitors.
    Schiesser S; Hajek P; Pople HE; Käck H; Öster L; Cox RJ
    Eur J Med Chem; 2022 Jan; 227():113925. PubMed ID: 34742013
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Novel 3H-[1,2,3]triazolo[4,5-c]pyridine derivatives as GPR119 agonists: Synthesis and structure-activity/solubility relationships.
    Matsuda D; Kobashi Y; Mikami A; Kawamura M; Shiozawa F; Kawabe K; Hamada M; Nishimoto S; Kimura K; Miyoshi M; Takayama N; Kakinuma H; Ohtake N
    Bioorg Med Chem; 2017 Aug; 25(16):4339-4354. PubMed ID: 28662959
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cytochrome P450 isoforms responsible for the N-deethylation and cyclohexane-hydroxylation of NS-21.
    Nakamura A; Hirota T; Morino A; Imaoka S; Funae Y; Yamamoto Y; Tasaki T; Masuda M; Kazusaka A; Fujita S
    Xenobiotica; 1999 Mar; 29(3):243-52. PubMed ID: 10219965
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Discovery of a subnanomolar and selective spirocyclic agonist of the glucocorticoid receptor.
    Badarau E; Robert F; Massip S; Jakob F; Lucas S; Friebe D; Hennen S; Frormann S; Ghosez L
    Eur J Med Chem; 2019 Jan; 161():354-363. PubMed ID: 30384041
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Synthesis and structure-activity relationship of fused-pyrimidine derivatives as a series of novel GPR119 agonists.
    Negoro K; Yonetoku Y; Moritomo A; Hayakawa M; Iikubo K; Yoshida S; Takeuchi M; Ohta M
    Bioorg Med Chem; 2012 Nov; 20(21):6442-51. PubMed ID: 23010456
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice.
    Yoshida S; Ohishi T; Matsui T; Tanaka H; Oshima H; Yonetoku Y; Shibasaki M
    Biochem Biophys Res Commun; 2010 Nov; 402(2):280-5. PubMed ID: 20937249
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold.
    Krasavin M; Lukin A; Zhurilo N; Kovalenko A; Zahanich I; Zozulya S; Moore D; Tikhonova IG
    Bioorg Med Chem; 2016 Jul; 24(13):2954-2963. PubMed ID: 27229618
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Inhibitory Effects of Trapping Agents of Sulfur Drug Reactive Intermediates against Major Human Cytochrome P450 Isoforms.
    Sodhi JK; Delarosa EM; Halladay JS; Driscoll JP; Mulder T; Dansette PM; Khojasteh SC
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28726718
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Design, synthesis and biological activity of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists.
    Li Z; Wang X; Xu X; Yang J; Xia W; Zhou X; Huang W; Qian H
    Bioorg Med Chem; 2015 Nov; 23(22):7158-64. PubMed ID: 26482570
    [TBL] [Abstract][Full Text] [Related]  

  • 76. C-Aryl glycoside inhibitors of SGLT2: Exploration of sugar modifications including C-5 spirocyclization.
    Robinson RP; Mascitti V; Boustany-Kari CM; Carr CL; Foley PM; Kimoto E; Leininger MT; Lowe A; Klenotic MK; Macdonald JI; Maguire RJ; Masterson VM; Maurer TS; Miao Z; Patel JD; Préville C; Reese MR; She L; Steppan CM; Thuma BA; Zhu T
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1569-72. PubMed ID: 20149653
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.
    Christiansen E; Urban C; Grundmann M; Due-Hansen ME; Hagesaether E; Schmidt J; Pardo L; Ullrich S; Kostenis E; Kassack M; Ulven T
    J Med Chem; 2011 Oct; 54(19):6691-703. PubMed ID: 21854074
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.
    Sasaki S; Kitamura S; Negoro N; Suzuki M; Tsujihata Y; Suzuki N; Santou T; Kanzaki N; Harada M; Tanaka Y; Kobayashi M; Tada N; Funami M; Tanaka T; Yamamoto Y; Fukatsu K; Yasuma T; Momose Y
    J Med Chem; 2011 Mar; 54(5):1365-78. PubMed ID: 21319751
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Design, synthesis, and biological evaluation of deuterated phenylpropionic acid derivatives as potent and long-acting free fatty acid receptor 1 agonists.
    Li Z; Liu C; Xu X; Shi W; Li H; Dai Y; Cai X; Huang W; Qian H
    Bioorg Chem; 2018 Feb; 76():303-313. PubMed ID: 29223807
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Metabolic Fate of the Isocyanide Moiety: Are Isocyanides Pharmacophore Groups Neglected by Medicinal Chemists?
    Galli U; Tron GC; Purghè B; Grosa G; Aprile S
    Chem Res Toxicol; 2020 Apr; 33(4):955-966. PubMed ID: 32212628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.